Policy

Insights

News

Testimony of BIO President & CEO John F. Crowley before the Senate Health, Education, Labor, and Pensions (HELP) Committee: “The Future of Biotech: Maintaining U.S. Competitiveness and Delivering Lifesaving Cures to Patients”

October 29, 2025

BIO Statement on Most Favored Nation

September 30, 2025

BIO Statement on Industry Tariffs

September 26, 2025

BIO Statement on Vaccines and Autism

September 23, 2025

Letters, Comments & Testimony

Testimony of BIO President & CEO John F. Crowley before the Senate Health, Education, Labor, and Pensions (HELP) Committee: “The Future of Biotech: Maintaining U.S. Competitiveness and Delivering Lifesaving Cures to Patients”

October 29, 2025

Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000 biotechnology companies, academic institutions, and research…

BIO Statement on Vaccines and Autism

September 23, 2025

Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating infectious diseases like smallpox, polio, and measles…

BIO's Comments to CDC’s Advisory Committee on Immunization Practices (ACIP)

September 16, 2025

Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in advance of the September 18-19th, 2025 meeting. BIO…

Co-Pay Accumulator Programs

Insurers and PBMs are implementing “co-pay accumulator” programs – an effort to prevent funds provided by manufacturer assistance programs from…

International Reference Pricing

Adopting foreign price controls on innovative medicines would severely chill investment in new cures and therapies for diseases and jeopardize access…